モーズレイ処方ガイドライン第14版（The Maudsley PrescribingGuidelines inPsychiatry 14thEdition）menu open
TOPうつ病と不安障害一般に認められている抗うつ薬の最小有効量

一般に認められている抗うつ薬の最小有効量

抗うつ薬の推奨される最小有効量を表3.2にまとめる。

表3.2　抗うつ薬の推奨される最小有効量

抗うつ薬 用量
三環系抗うつ薬 不明。少なくとも75-100mg/日1，125mg/日の場合もある2
ロフェプラミン 140mg/日3
SSRI
citalopram 20mg/日4
エスシタロプラム 10mg/日5
fluoxetine 20mg/日6
フルボキサミン 50mg/日7
パロキセチン 20mg/日8
セルトラリン 50mg/日9
その他
agomelatine 25mg/日10
bupropion 150mg/日11
desvenlafaxine 50mg/日12
デュロキセチン 60mg/日13, 14
levomilnacipran 40mg/日15
ミルタザピン 30mg/日（15mg？16）
moclobemide 300mg/日17
reboxetine 8mg/日18
トラゾドン 150mg/日19
ベンラファキシン 75mg/日20
vilazodone 20mg/日15
ボルチオキセチン 10mg/日15

（桐野　創）

参照文献
  1. Furukawa TA, et al. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. BMJ 2002; 325:991.
  2. Donoghue J, et al. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000; 13:365-368.
  3. Lancaster SG Lancaster SG, et al. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1989; 37:123-140.
  4. Montgomery SA, et al. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994; 9 Suppl 1:35-40.
  5. Burke WJ, et al. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63:331-336.
  6. Altamura AC, et al. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry Suppl 1988; 109-112.
  7. Walczak DD, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996; 8:139-151.
  8. Dunner DL, et al. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992; 53 Suppl:21-26.
  9. Moon CAL, et al. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associative anxiety in general practice. J Psychopharm 1994; 8:171-176.
  10. Loo H, et al. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17:239-247.
  11. Hewett K, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacology 2009; 23:531-538.
  12. GolKornstein SG, et al. The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Human Psychopharmacology 2014; 29:492-501.
  13. Goldstein DJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24:389-399.
  14. Detke MJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63:308-315.
  15. He H, et al. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: a PRISMA-compliant meta-analysis. J Psychiatr Res 2018; 96:247-259.
  16. Furukawa TA, et al. No benefit from flexible titration above minimum licensed dose in prescribing antidepressants for major depression: systematic review. Acta Psychiatr Scand 2020; 141:401-409.
  17. Priest RG, et al. Moclobemide in the treatment of depression. Rev Contemporary Pharmacother 1994; 5:35-43.
  18. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000; 61 Suppl 10:31-38.
  19. Brogden RN, et al. Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs 1981; 21:401-429.
  20. Feighner JP, et al. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47:55-62.